Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Shares Issued (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Shares Issued over the past 13 years, most recently at $23.8 million for Q2 2025.

  • Quarterly results put Shares Issued at $23.8 million for Q2 2025, up 3394.2% from a year ago — trailing twelve months through May 2025 was $23.8 million (changed N/A YoY), and the annual figure for FY2025 was $23.8 million, changed.
  • Shares Issued for Q2 2025 was $23.8 million at Lifecore Biomedical, Inc. \De\, up from -$23.8 million in the prior quarter.
  • Over the last five years, Shares Issued for LFCR hit a ceiling of $23.8 million in Q2 2025 and a floor of -$23.8 million in Q1 2025.
  • Median Shares Issued over the past 4 years was $1000.0 (2024), compared with a mean of $2.6 million.
  • Biggest five-year swings in Shares Issued: plummeted 99.86% in 2024 and later surged 3394.2% in 2025.
  • Lifecore Biomedical, Inc. \De\'s Shares Issued stood at $5.0 million in 2022, then plummeted by 85.52% to $724000.0 in 2023, then skyrocketed by 3192.82% to $23.8 million in 2024, then rose by 0.04% to $23.8 million in 2025.
  • The last three reported values for Shares Issued were $23.8 million (Q2 2025), -$23.8 million (Q1 2025), and $23.8 million (Q4 2024) per Business Quant data.